These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 11772120)

  • 1. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.
    Ross GW; Petrovitch H
    Drugs Aging; 2001; 18(11):797-806. PubMed ID: 11772120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
    Kalda A; Yu L; Oztas E; Chen JF
    J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
    Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
    Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.
    Schwarzschild MA; Chen JF; Ascherio A
    Neurology; 2002 Apr; 58(8):1154-60. PubMed ID: 11971080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
    Chen JF; Xu K; Petzer JP; Staal R; Xu YH; Beilstein M; Sonsalla PK; Castagnoli K; Castagnoli N; Schwarzschild MA
    J Neurosci; 2001 May; 21(10):RC143. PubMed ID: 11319241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: A (13)C NMR study.
    Bagga P; Chugani AN; Patel AB
    Neurochem Int; 2016 Jan; 92():25-34. PubMed ID: 26626997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
    Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
    Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism.
    Singh K; Singh S; Singhal NK; Sharma A; Parmar D; Singh MP
    Chem Biol Interact; 2010 Apr; 185(2):81-93. PubMed ID: 20230807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Caffeine as a preventive drug for Parkinson's disease: epidemiologic evidence and experimental support].
    Góngora-Alfaro JL
    Rev Neurol; 2010 Feb 16-28; 50(4):221-9. PubMed ID: 20198594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse.
    Pierri M; Vaudano E; Sager T; Englund U
    Neuropharmacology; 2005 Mar; 48(4):517-24. PubMed ID: 15755479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection.
    Singh S; Singh K; Patel DK; Singh C; Nath C; Singh VK; Singh RK; Singh MP
    Rejuvenation Res; 2009 Jun; 12(3):185-97. PubMed ID: 19594327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Xu K; Xu Y; Brown-Jermyn D; Chen JF; Ascherio A; Dluzen DE; Schwarzschild MA
    J Neurosci; 2006 Jan; 26(2):535-41. PubMed ID: 16407551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
    Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
    Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
    Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.
    Singh S; Singh K; Patel S; Patel DK; Singh C; Nath C; Singh MP
    Brain Res; 2008 May; 1207():193-206. PubMed ID: 18374908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
    Schwarzschild MA; Xu K; Oztas E; Petzer JP; Castagnoli K; Castagnoli N; Chen JF
    Neurology; 2003 Dec; 61(11 Suppl 6):S55-61. PubMed ID: 14663012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.